Victory Capital Management
BXRX

Victory Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Victory Capital Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9
Closed -$3K – 2877
2021
Q4 		$3K Hold
9
– – ﹤0.01% 2761
2021
Q3 		$7K Hold
9
– – ﹤0.01% 2770
2021
Q2 		$10K Buy
9
+1
+13% +$1.31K ﹤0.01% 2733
2021
Q1 		$15K Buy
+8
New +$16K ﹤0.01% 2731
2020
Q2 		– Sell
-2
Closed -$8K – 3584
2020
Q1 		$8K Hold
2
– – ﹤0.01% 3401
2019
Q4 		$15K Buy
+2
New +$17.1K ﹤0.01% 2618

Other funds holding BXRX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Victory Capital Management's BXRX Position: Q1 2022 in Review

Victory Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2022, closing a stake of 9 shares — an estimated $3K sold.

Victory Capital Management first reported a position in BXRX in Q4 2019 and held it in 6 quarters. The position peaked at $15K in Q1 2021. 19 funds tracked by Wall St. Rank hold BXRX as of Q1 2022.

  • Victory Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Victory Capital Management sold 9 Baudax Bio, Inc. Common Stock shares in Q1 2022, an estimated $3K.
  • Victory Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • Victory Capital Management's Baudax Bio, Inc. Common Stock position peaked at $15K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2022.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.